AKUR8
27.7.2021 09:02:06 CEST | Business Wire | Press release
Akur8 is pleased to announce its collaboration with Beesafe and Compensa, two entities of VIG Poland, to enhance their pricing process. With this new milestone, Akur8 continues to expand its European footprint, with 7 countries to date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005010/en/
Specifically developed for insurers, Akur8’s solution boosts their pricing processes by automating risk and demand modeling, using transparent Artificial Intelligence proprietary technology. The core benefit for insurers is greater speed-to-accuracy, while maintaining full transparency and control on the models created.
VIG (Vienna Insurance Group) is one of the largest insurance groups in the world and one of the leading insurers in Austria and CEE countries. By collaborating with Akur8 for their motor insurance lines, Compensa will further accelerate their digital transformation, transforming the very core pricing process. Beesafe, a new, fully digital and direct entity created by VIG Poland, will be using Akur8 to launch their new product, leveraging the accelerated time-to-market benefits.
“We are very happy to support Beesafe and Compensa, part of VIG Poland, in taking a critical step towards insurance pricing sophistication and spurring digital transformation in their field. We are particularly humbled to accompany Beesafe in the launch of their fully digital journey, to help them bring their product to Polish consumers in a timely manner.”, says Samuel Falmagne, CEO at Akur8.
“It is great to be able to support VIG Poland in the launch of a new venture, whilst also reinforcing Akur8’s presence in Europe, Poland being our seventh European country of presence to date.”, says Brune de Linares, Chief of Sales at Akur8.
“Beesafe is a purely digital venture with a strong insurtech identity that we are extremely proud to be launching despite a very challenging context undermined by Covid. This is a strong testimony to the team’s commitment to continue to fuel digital transformation in our sector, sustained by collaborations with top-notch solutions that Akur8 epitomizes, for a highly strategic process that is pricing, all the more when launching a new product.”, says Rafał Mosionek, CEO at Beesafe and Executive Committee Member at Compensa, VIG Poland.
About Akur8
Akur8
is revolutionizing insurance pricing with transparent AI. Akur8 developed a unique AI-based insurance pricing solution that automates modeling for insurance companies while keeping full transparency and control on the models created, as required by regulators worldwide. Akur8 is the only solution on the market reconciling Machine Learning and Actuarial worlds.
About Beesafe
Beesafe
is a digital venture with a strong insurtech identity, benefiting from a quite unique positioning within the CEE area. The digital start-up was established by VIG, the leading insurance group in Austria, Central and Eastern Europe, to provide a dynamic distribution company with a unique customer offering, and potential for expansion into other countries where VIG operates.
About Compensa
Part of the Vienna Insurance Group, Compensa has been operating on the Polish market for many years, constantly developing its offer, service standards and sales network to exceed the expectations of the growing number of customers.
About VIG
Vienna Insurance Group (VIG)
is a leading specialist insurance company in Austria and Central and Eastern Europe. About 50 companies in 30 countries belong to it. It is a company with a long tradition, having strong brands and attaching great importance to customer proximity. VIG bases its activity on the foundation of almost 200 years of experience in the insurance industry. The Vienna Insurance Group, with around 25,000 employees, is the undisputed leader in the group's key markets and thus has an excellent market position enabling it to take advantage of long-term growth opportunities in a region with 180 million people.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005010/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
